Clinical Pharmacology & Therapeutics· 2015Q1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for <i>CYP3A5</i> Genotype and Tacrolimus Dosing
- 696citations
- Q1SCImago
- 2015year
Short summary
New CPIC guidelines recommend adjusting tacrolimus dosing based on CYP3A5 genotype to improve immunosuppression after transplantation.
AI-generated from the title and abstract; the full text is not read.
Key points
- Tacrolimus dosing should be guided by CYP3A5 genotype.
- CYP3A5 expressers (extensive/intermediate metabolizers) generally need higher tacrolimus doses.
- CYP3A5 non-expressers (poor metabolizers) may achieve target concentrations with lower doses.
- These recommendations aim to optimize immunosuppression and achieve target blood concentrations faster post-transplant.
AI-generated from the title and abstract; the full text is not read.
Abstract
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
The authors' abstract, as published at the source. Clinical Pharmacology & Therapeutics, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Transplantation
TransplantationMedicine